Organon & Co

Country
United States
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
10,000
Ticker
OGN
Exchange
NEW YORK STOCK EXCHANGE, INC.
Description
Organon & Co. is a global healthcare company that focuses primarily on the discovery, development, manufacture, and commercialization of therapeutic solutions. Its primary function is to address the n...

Financial Statements of Organon & Co

Below are the financial statements of Organon & Co, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

All figures in millions of USD202420232022
Revenues
6,403a
6,263a
6,174a
Cost of sales
-2,688a
-2,515a
-2,294a
Gross profit
3,715a
3,748a
3,880a
Selling, general and administrative
-1,760a
-1,893a
-1,704a
Research and development
-469a
-528a
-471a
Acquired in-process research and development and milestones
-81a
-8a
-107a
Restructuring costs
-31a
-62a
-28a
Interest expense
-520a
-527a
-422a
Exchange losses
-26a
-42a
-11a
Other expense, net
-21a
-15a
-15a
Income before income taxes
807a
673a
1,122a
Income tax (benefit) expense
-57a
-350a
-205a
Net income
864a
1,023a
917a

Verified Sources Behind Organon & Co’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Organon & Co’s data sources below and access millions more through our Disclosure Search.

a. Organon & Co's 10-K 2024
Trace every data point back to Organon & Co’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?